To keep you up-to-date on the latest scientific findings and on the clinical management of CML the iCMLf is pleased to present to you monthly updates from key CML publications in peer-reviewed journals. 

The iCMLf 'Publications of the month' are brought to you by Professor Timothy Hughes . From the many papers on CML published this month Professor Hughes has selected topical, interesting papers for your perusal including interesting articles from the emerging economic regions and recent papers on CML and COVID-19.

Read Professor Hughes' CML publications of the month: February 2021

Clinical papers

• Clinical outcomes of patients with chronic myeloid leukemia with concurrent core binding factor rearrangement and Philadelphia chromosome
  Morita K et al. Clin Lymphoma Myeloma Leuk, January 2021 (epub ahead of print)
• Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKI’s: First interim analysis of OPTkIMA study
  Malagola M et al. Cancer Med, February 2021 (epub ahead of print) - open access publication
• Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR – final report from AFTER-SKI
  Richter J et al. Leukemia, February 2021 (epub ahead of print) – open access publication
  
• Mortality rates in patients with chronic myeloid leukemia in chronic phase with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)
  Breccia M et al. Ann Hematol, February 2021
  

Scientific papers

• Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
  Clark RE et al. Blood Adv, February 2021 - open access publication
• Eradicating residual chronic myeloid leukemia: basic research lost in translation
  Zhao H and Deininger M. Lancet Haematol, February 2021
• Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFTM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib
  Hrdinova T et al. Int J Oncol, February 2021

COVID-19 and CML/Cancer

• Lymphopenia as a biological predictor of outcomes in COVID-19 patients: A Nationwide Cohort Study
  Lee J et al. Cancers(Basel), January 2021 – open access publication
• Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19
  Jacobs CF et al. Blood Adv, February 2021 - open access publication
• Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time
  Cattaneo C et al. Leukemia, February 2021 – open access publication
• Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward
  Gupta K et al. Cancer Treat Res Commun 2021 - open access publication